Want to see AU:HPC full AI Analyst Report?
Hydration Pharmaceuticals Co. Ltd. (HPC) AI Stock Analysis
Hydration Pharmaceuticals Co. Ltd.
(ASX:HPC)
The score reflects severe financial distress and poor valuation. Financial performance shows collapsing revenue, negative margins, and cash burn, with a thin equity cushion. Valuation offers no offset, as negative P/E and penny stock status indicate high risk. The company is highly speculative and faces solvency concerns.
Hydration Pharmaceuticals Co. Ltd. (HPC) vs. iShares MSCI Australia ETF (EWA)
Not enough price history over this period.
- Market Cap
- AUD 1.61M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- 1.25
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Australia
- Employees
- 3
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Food Distribution
Hydration Pharmaceuticals Co. Ltd. Business Overview & Revenue Model
Company Description
The Hydration Pharmaceuticals Company Limited, established in 2001, provides a diverse portfolio of healthy hydration remedies, offered as liquids, tablets, and powders. Operating from its headquarters in San Diego, California, the company distribute...
How the Company Makes Money
null
Hydration Pharmaceuticals Co. Ltd. Financial Statement Overview
Summary
Income statement score 15, balance sheet 25, and cash flow 10 reflect severe distress. Revenue collapsed from $10.0M to $2.6M, margins deeply negative, and cash burn persists. Debt-free status provides some relief but equity is thin. Urgent need for turnaround or capital.
Income Statement
15Very NegativeBalance Sheet
25NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.14M | 2.56M | 3.20M | 10.04M | 9.10M | 6.13M |
| Gross Profit | 18.49K | -27.42K | 1.62M | 5.39M | 4.70M | 2.79M |
| EBITDA | -2.71M | -3.26M | 286.28K | 0 | -10.51M | -6.08M |
| Net Income | -2.48M | -2.96M | 2.67M | -8.10M | -10.61M | -8.97M |
Balance Sheet | ||||||
| Total Assets | 1.24M | 2.19M | 5.00M | 6.69M | 10.39M | 15.31M |
| Cash, Cash Equivalents and Short-Term Investments | 442.73K | 1.12M | 3.22M | 1.84M | 4.69M | 10.67M |
| Total Debt | 0 | 0 | 0 | 3.89M | 3.71M | 0 |
| Total Liabilities | 581.54K | 774.76K | 2.25M | 7.05M | 6.41M | 2.08M |
| Stockholders Equity | 656.00K | 1.42M | 2.74M | -358.25K | 3.98M | 13.23M |
Cash Flow | ||||||
| Free Cash Flow | -3.10M | -3.78M | -3.02M | -5.73M | -9.75M | -8.08M |
| Operating Cash Flow | -3.10M | -3.78M | -3.02M | -5.73M | -9.75M | -8.08M |
| Investing Cash Flow | 0 | 0 | 9.44M | 0 | 0 | -2,151 |
| Financing Cash Flow | 594.36K | 833.93K | -3.63M | 2.72M | 4.08M | 17.03M |
Hydration Pharmaceuticals Co. Ltd. Peers Comparison
Overall Rating
AU:CLV77Outperform
AU:BUB48Neutral
AU:NUC46Neutral
AU:AHF45Neutral- AU:HPC41Neutral
AU:NGS26Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:CLV | 77Outperform | AUD 167.00M | 15.97 | 13.83% | 2.42% | 13.26% | 49.05% |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| AU:BUB | 48Neutral | AUD 69.82M | -15.00 | -11.08% | ― | 9.08% | -183.87% |
| AU:NUC | 46Neutral | AUD 12.55M | -1.68 | -88.51% | ― | 11.96% | -81.99% |
| AU:AHF | 45Neutral | AUD 12.97M | -4.21 | -12.90% | ― | 0.46% | 46.48% |
| AU:HPC | 41Neutral | AUD 1.61M | -0.37 | -239.37% | ― | ― | ― |
| AU:NGS | 26Underperform | AUD 18.32M | -0.01 | -130.72% | ― | -33.05% | 94.22% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:HPC | Hydration Pharmaceuticals Co. Ltd. | ― | ― | ― | |
| AU:AHF | Australian Dairy Nutritionals Group | 0.02 | -0.02 | -54.29% | |
| AU:BUB | Bubs Australia Ltd. | 0.08 | -0.07 | -48.00% | |
| AU:NUC | Nuchev Pty Ltd | 0.08 | -0.06 | -42.86% | |
| AU:NGS | Nutritional Growth Solutions Ltd. | 0.02 | -0.00 | -9.52% | |
| AU:CLV | Clover Corporation Limited | 1.00 | 0.34 | 50.60% |
Hydration Pharmaceuticals Co. Ltd. Corporate Events
Hydralyte USA Boosts Sales and Tightens Costs Amid Strategic Review
Hydration Pharmaceuticals Co. Ltd., trading as Hydralyte USA, operates in the hydration solutions industry, selling electrolyte products across online and offline channels in North America. The company is focusing on cost control, margin enhancement,...
Hydration Pharmaceuticals appoints new director without equity stake
Hydration Pharmaceuticals Co. Ltd. has appointed Nick Katiforis as a director effective 24 June 2026, expanding its board as disclosed in an initial director’s interest notice to the ASX. The filing confirms that Katiforis currently holds no re...
Hydration Pharmaceuticals Director Karafili Steps Down but Retains Significant Indirect Stake
Hydration Pharmaceuticals Company Limited has announced that director Adem Karafili ceased to serve as a director on 24 June 2026, formally notifying the ASX in line with listing rule requirements. The notice confirms that while Karafili holds no sec...
Hydralyte USA completes major share issue and reshapes board
Hydration Pharmaceuticals Company Limited, known as Hydralyte USA, is a hydration solutions provider listed on the ASX that offers oral rehydration products to consumers and is positioning itself for further expansion in its market. The company conti...
Hydration Pharmaceuticals Seeks ASX Quotation for 98 Million New Shares
The Hydration Pharmaceuticals Company Limited has applied for quotation on the ASX of 98,000,000 ordinary fully paid shares under the code HPC, with an issue date of June 23, 2026. The move formalises the listing of these securities, expanding the co...
Hydration Pharmaceuticals Plans Major Share Placement on ASX
Hydration Pharmaceuticals has notified the ASX of a proposed equity issue comprising up to 98 million ordinary fully paid shares under a placement or similar structure. The securities are intended for quotation on the ASX from 17 June 2026, signallin...
Hydration Pharmaceuticals Refocuses HydraLyte Strategy on U.S. Market
Hydration Pharmaceuticals has repositioned itself as a pure-play U.S. hydration business after selling its Canadian and rest-of-world operations in October 2024 and having previously divested its Australian business in 2014. The company now concentra...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 04, 2026